New drug aims to heal bile ducts in liver transplant patients
NCT ID NCT07305363
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a drug called seladelpar in 10 adults who have bile duct damage (ischemic cholangiopathy) after a liver transplant. The goal is to see if the drug can improve liver enzyme levels and is safe. Participants will take the drug for 26 weeks and be monitored closely.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ISCHEMIC CHOLANGIOPATHY are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can immune cells predict herpesvirus danger in transplant patients?
- Can a helping hand ease the burden of pediatric liver transplants?
- Can a helping hand ease the leap to adult transplant care?
- Can we safely skip a Pre-Transplant bile duct scan? a trial tests the limits of simpler donor checks
- Could a common drug stop a rare liver disease from returning after transplant?
- New study examines artery complications in child liver transplants